Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.

“MedCity is invaluable among the many sources of industry reporting because the team endeavor to bring the truly new, and innovative opportunities and developments to light.”

Ken Kirby, President, Transdermal Delivery Solutions Corp

Sign up for our daily newsletter

Lilly to stop rheumatoid arthritis drug trial due to lack of efficacy

December 13, 2012 8:18 am by | 0 Comments

(Reuters) - Eli Lilly and Co said it will stop one of three late-stage trials of its rheumatoid arthritis drug tabalumab due to insufficient efficacy.

The decision was not based on safety concerns, and patients currently enrolled in other tabalumab rheumatoid arthritis studies will continue treatment, Lilly said.

The decision to stop the study, called FLEX-M, is expected to result in an after-tax charge of about 2 cents per share in the fourth quarter.

(Reporting by Esha Dey in Bangalore; Editing by Joyjeet Das)


Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.